Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
NXS | Ann: Investor Presentation | 01/03/21 | 17 | 3.2K | |||
|
|||||||
NXS | Ann: Appendix 4E / FY20 Financial Statements | 24/02/21 | 3 | 554 | |||
|
|||||||
NXS | Ann: Full Year Results Investor Briefing Script | 24/02/21 | 2 | 493 | |||
|
|||||||
NXS | Next Science Price Target Raised 16% to A$1.51/Share by Bell Potter | 23/02/21 | 0 | 137 | |||
|
|||||||
NXS | Charts NXS | 23/02/21 | 697 | 944K | |||
|
|||||||
NXS | What is the level of post surgical infections Case study | 23/02/21 | 0 | 86 | |||
|
|||||||
NXS | News: NXS Next Science Ltd Says FY Revenues From Ordinary Activities Down 15% To USD$3.4 Million | 22/02/21 | 1 | 274 | |||
|
|||||||
NXS | Ann: Next Science receives CE Mark approval for BlastX | 20/02/21 | 8 | 3.3K | |||
|
See All Discussions
Timeline
![]() |
|
||||
![]() |
|
||||
![]() |
|
||||
![]() |
|
||||
![]() |
|
||||
![]() |
|
||||
View More |